Recent reports suggest increased antitumor efficacy in syngeneic mouse tumor models treated with both the GLS inhibitor CB-839 and either anti-PD1 or anti-PDL1 immune checkpoint inhibitors [54]. The gene discussed is CD274; the disease is neoplasm.